Expert Interview
A Third Take: Looking at Momelotinib & Pacritinib in treating Myelofibrosis
Ticker(s): SRRA, CTICInstitution: MD Anderson
- Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center & Director of the Clinical Research Center for MPNs.
- Treats 700 patients per year with Myelofibrosis.
- Clinical and translational research is focused on understanding the biology of and developing new therapies for myeloproliferative neoplasms (MPNs); has been principal investigator for more than 50 clinical trials testing novel therapies for patients with MPNs and has published more than 400 peer-reviewed manuscripts.
Please describe your clinical practice and research relating to MF.
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Momelotinib? on Pacritinib?
Added By: c_adminWhat do you expect the Danazol arm to do on A) TSS B) TI C) SVR?
What do you expect the Momelotinib arm to do on A) TSS B) TI C) SVR?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
